The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Recent advances in hepatocellular carcinoma therapy
Open accessAbstract
Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies
Bertino, G., Demma, S., Ardiri, A., Proiti, M., Malaguarnera, G., Bertino, N., Malaguarnera, M., & Malaguarnera, M. (2014) · BioMed Research International · doi:10.1155/2014/203693 · Cited by 79
RetractedManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
Evans, M. J., von Hahn, T., Tscherne, D. M., Syder, A. J., Panis, M., Wölk, B., Hatziioannou, T., McKeating, J. A., Bieniasz, P. D., & Rice, C. M. (2007) · Nature · doi:10.1038/nature05654 · Cited by 1,232
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Mechanisms of HBV-induced hepatocellular carcinoma
Levrero, M., & Zucman-Rossi, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.021 · Cited by 1,052
Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,024
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
Ploss, A., Evans, M. J., Gaysinskaya, V. A., Panis, M., You, H., de Jong, Y. P., & Rice, C. M. (2009) · Nature · doi:10.1038/nature07684 · Cited by 941
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Macrophages, Immunity, and Metabolic Disease
McNelis, J. C., & Olefsky, J. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.010 · Cited by 720
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · cited 1×
“Even the potential role of TNF-α, NFΚb, IL-1, CXC chemokines from activated Kupffer cells, Toll-like receptors (TLRs) from damage-associated molecular patterns (DAMPs) of damaged hepatocytes are found to play crucial roles in the NASH-related HCC (Kubes & Mehal, 2012; Nakagawa et al., 2014).”
BackgroundCainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
In vivo activity of nuclease-resistant siRNAs
LAYZER, J. M., MCCAFFREY, A. P., TANNER, A. K., HUANG, Z., KAY, M. A., & SULLENGER, B. A. (2004) · RNA · doi:10.1261/rna.5239604 · Cited by 580
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Zhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Immunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Effects of Microrna-29 on Apoptosis, Tumorigenicity, and Prognosis of Hepatocellular Carcinoma
Xiong, Y., Fang, J.-H., Yun, J.-P., Yang, J., Zhang, Y., Jia, W.-H., & Zhuang, S.-M. (2010) · Hepatology · doi:10.1002/hep.23380 · Cited by 563
ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M. A., Seki, E., Hidalgo, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.001 · Cited by 525
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region
Zhu, R. X., Seto, W.-K., Lai, C.-L., & Yuen, M.-F. (2016) · Gut and Liver · doi:10.5009/gnl15257 · Cited by 502
Bai, S., Nasser, M. W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., & Ghoshal, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016774 · Cited by 477
Sainz, B., Barretto, N., Martin, D. N., Hiraga, N., Imamura, M., Hussain, S., Marsh, K. A., Yu, X., Chayama, K., Alrefai, W. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2581 · Cited by 452
Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma
Sohn, W., Kim, J., Kang, S. H., Yang, S. R., Cho, J.-Y., Cho, H. C., Shim, S. G., & Paik, Y.-H. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.68 · Cited by 426
Fang, Y., Xue, J.-L., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425
Lv, L.-H., Wan, Y.-L., Lin, Y., Zhang, W., Yang, M., Li, G.-L., Lin, H.-M., Shang, C.-Z., Chen, Y.-J., & Min, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340588 · Cited by 420
Timpe, J. M., Stamataki, Z., Jennings, A., Hu, K., Farquhar, M. J., Harris, H. J., Schwarz, A., Desombere, I., Roels, G. L., Balfe, P., et al. (2008) · Hepatology · doi:10.1002/hep.21959 · Cited by 389
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
Pirazzi, C., Valenti, L., Motta, B. M., Pingitore, P., Hedfalk, K., Mancina, R. M., Burza, M. A., Indiveri, C., Ferro, Y., Montalcini, T., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu121 · Cited by 363
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma
Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Tanemura, M., Tomokuni, A., Takemasa, I., Umeshita, K., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.026 · Cited by 361
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Dhir, M., Melin, A. A., Douaiher, J., Lin, C., Zhen, W. (., Hussain, S. M., Geschwind, J.-F. H., Doyle, M. B. M., Abou-Alfa, G. K., & Are, C. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001556 · Cited by 285
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
Fate of fat: The role of adipose triglyceride lipase in lipolysis
Zimmermann, R., Lass, A., Haemmerle, G., & Zechner, R. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.10.005 · Cited by 246
Claudin Association with CD81 Defines Hepatitis C Virus Entry
Harris, H. J., Davis, C., Mullins, J. G. L., Hu, K., Goodall, M., Farquhar, M. J., Mee, C. J., McCaffrey, K., Young, S., Drummer, H., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.104836 · Cited by 237
Thakral, S., & Ghoshal, K. (2015) · Current Gene Therapy · doi:10.2174/1566523214666141224095610 · Cited by 235
Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
Yang, N., Ekanem, N. R., Sakyi, C. A., & Ray, S. D. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.029 · Cited by 230
MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma
Hayes, C., & Chayama, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030280 · Cited by 223
Guy, C. D., Suzuki, A., Zdanowicz, M., Abdelmalek, M. F., Burchette, J., Unalp, A., & Diehl, A. M. (2012) · Hepatology · doi:10.1002/hep.25559 · Cited by 218
Grarup, N., Sandholt, C. H., Hansen, T., & Pedersen, O. (2014) · Diabetologia · doi:10.1007/s00125-014-3270-4 · Cited by 201
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195
A fresh look at NASH pathogenesis. Part 1: The metabolic movers
Larter, C. Z., Chitturi, S., Heydet, D., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06253.x · Cited by 180
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Lo, A., Lin, C.-T., & Wu, H.-C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2359 · Cited by 179
Komori, H., Nakatsura, T., Senju, S., Yoshitake, Y., Motomura, Y., Ikuta, Y., Fukuma, D., Yokomine, K., Harao, M., Beppu, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2267 · Cited by 175
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
Reeves, H. L., Zaki, M. Y. W., & Day, C. P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4085-6 · Cited by 166
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities
Pardee, A. D., & Butterfield, L. H. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18344 · Cited by 160
Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC
Fornari, F., Ferracin, M., Treré, D., Milazzo, M., Marinelli, S., Galassi, M., Venerandi, L., Pollutri, D., Patrizi, C., Borghi, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141448 · Cited by 159
New advances in hepatocellular carcinoma
Pascual, S., Herrera, I., & Irurzun, J. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i9.421 · Cited by 156
Elimination Pathways of Systemically Delivered siRNA
Huang, Y., Hong, J., Zheng, S., Ding, Y., Guo, S., Zhang, H., Zhang, X., Du, Q., & Liang, Z. (2010) · Molecular Therapy · doi:10.1038/mt.2010.266 · Cited by 152
Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Mirzaei, H. R., Sahebkar, A., Mohammadi, M., Yari, R., Salehi, H., Jafari, M., Namdar, A., Khabazian, E., Jaafari, M. R., & Mirzaei, H. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160303110838 · Cited by 151
Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy
Cai, Y., Xu, Y., Chan, H. F., Fang, X., He, C., & Chen, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00677 · Cited by 150
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
Haruyama, Y., & Kataoka, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.275 · Cited by 142
Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.004 · Cited by 137
Hepatocellular carcinoma: Where are we?
Mazzanti, R., Arena, U., & Tassi, R. (2016) · World Journal of Experimental Medicine · doi:10.5493/wjem.v6.i1.21 · Cited by 130
Targeted therapy for hepatocellular carcinoma
Spangenberg, H. C., Thimme, R., & Blum, H. E. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.86 · Cited by 124
Zhang, J., Hu, J., Chan, H. F., Skibba, M. E., Liang, G., & Chen, M. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.01.017 · Cited by 112
Varshosaz, J., & Farzan, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.12022 · Cited by 104
Pathogenesis of alcoholic liver disease
Sugimoto, K., & Takei, Y. (2016) · Hepatology Research · doi:10.1111/hepr.12736 · Cited by 99
Wu, X., Chen, J., Li, X., Zhao, Y., & Zughaier, S. M. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.04.010 · Cited by 98
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., & Nishimura, Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1177 · Cited by 97
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Lee, R. J., Lee, R. J., Zhang, Yung, Li, Zhou, C., & Lee, L. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33965 · Cited by 94
Thapa, R. K., Choi, J. Y., Poudel, B. K., Tran, T. H., Pathak, S., Gupta, B., Choi, H., Yong, C. S., & Kim, J. O. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b06203 · Cited by 91
Wang, J., Wang, H., Li, J., Liu, Z., Xie, H., Wei, X., Lu, D., Zhuang, R., Xu, X., & Zheng, S. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03166 · Cited by 86
Multimodal approaches to the treatment of hepatocellular carcinoma
Cabibbo, G., Latteri, F., Antonucci, M., & Craxì, A. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1357 · Cited by 83
Chen, F., Zhang, J., Wang, L., Wang, Y., & Chen, M. (2015) · Nanoscale · doi:10.1039/c5nr04612b · Cited by 81
Ikeda, M., Ohkawa, S., Okusaka, T., Mitsunaga, S., Kobayashi, S., Morizane, C., Suzuki, I., Yamamoto, S., & Furuse, J. (2014) · Cancer Science · doi:10.1111/cas.12368 · Cited by 77
Pinter, M., Ulbrich, G., Sieghart, W., Kölblinger, C., Reiberger, T., Li, S., Ferlitsch, A., Müller, C., Lämmer, J., & Peck‐Radosavljevic, M. (2015) · Radiology · doi:10.1148/radiol.2015142140 · Cited by 76
Okajima, W., Komatsu, S., Ichikawa, D., Miyamae, M., Kawaguchi, T., Hirajima, S., Ohashi, T., Imamura, T., Kiuchi, J., Arita, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10781 · Cited by 74
Xu, Y., Guo, X., Tu, L., Zou, Q., Li, Q., Tang, C., Chen, B., Wu, C., & Wei, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87011 · Cited by 72
Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging
Zhu, D., Qin, Y., Wang, J., Zhang, L., Zou, S., Zhu, X., & Zhu, L. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00030 · Cited by 70
Wang, C., Su, L., Wu, C., Wu, J., Zhu, C., & Yuan, G. (2016) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2016.1185435 · Cited by 69
Advanced Hepatocellular Cancer: the Current State of Future Research
Connell, L. C., Harding, J. J., & Abou‐Alfa, G. K. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0415-3 · Cited by 64
Systemic therapies for hepatocellular carcinoma
Ge, S., & Huang, D. (2015) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2015.01047 · Cited by 58
Zhang, J., Zhang, M., Ji, J., Fang, X., Pan, X., Wang, Y., Wu, C., & Chen, M. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1714-2 · Cited by 57
Jiang, J., Chen, H., Yu, C., Zhang, Y., Chen, M., Tian, S., & Sun, C. (2015) · Nanomedicine · doi:10.2217/nnm.15.43 · Cited by 56
Mizukoshi, E., Nakagawa, H., Kitahara, M., Yamashita, T., Arai, K., Sunagozaka, H., Iida, N., Fushimi, K., & Kaneko, S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.020 · Cited by 47
Zhang, X., Li, J., & Yan, M. (2016) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2016.1160103 · Cited by 45
Progress in the development of vaccines for hepatitis C virus infection
Ghasemi, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.11984 · Cited by 45
Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments
Trojan, J., Zangos, S., & Schnitzbauer, A. A. (2016) · Visceral Medicine · doi:10.1159/000445730 · Cited by 43
Medina, S. H., Tiruchinapally, G., Chevliakov, M. V., Durmaz, Y. Y., Stender, R., Ensminger, W. D., Shewach, D. S., & ElSayed, M. E. H. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201200406 · Cited by 42
Cell Death-Inducing DFFA-Like Effector b Is Required for Hepatitis C Virus Entry into Hepatocytes
Wu, X., Lee, E. M., Hammack, C., Robotham, J. M., Basu, M., Lang, J., Brinton, M. A., & Tang, H. (2014) · Journal of Virology · doi:10.1128/jvi.00081-14 · Cited by 42
Xiang, G., Zhou, T., Zhang, L., Peng, F., Huang, Y., Ye, P., Lu, M., Yang, G., Gai, Y., Tan, Y., et al. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79598 · Cited by 41
Simonelli, M., Zucali, P. A., Santoro, A., Thomas, M. B., de Braud, F., Borghaei, H., Berlin, J. D., Denlinger, C. S., Noberasco, C., Rimassa, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw240 · Cited by 41
Li, X., Liu, Y., Wu, X., Gao, Y., Zhang, J., Zhang, D., Gu, S., Zhu, G., & Liu, G. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s108128 · Cited by 41
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use
Hong, Y., Li, Z.-D., Prasoon, P., & Zhang, Q. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.980 · Cited by 40
Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials
Sun, Z., Zhu, Y., Xia, J., Sawakami, T., Kokudo, N., & Zhang, N. (2015) · BioScience Trends · doi:10.5582/bst.2015.01128 · Cited by 39
Wang, Q., Wang, N., Shen, D., Sun, X., Cao, X., & Wu, D. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s92378 · Cited by 39
Novel drugs in clinical development for hepatocellular carcinoma
Waidmann, O., & Trojan, J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1058776 · Cited by 38
Pathak, P. O., Dhawan, V. V., Magarkar, A., Danne, R., Govindarajan, S., Ghosh, S., Steiniger, F., Chaudhari, P. R., Gopal, V., Bunker, A., et al. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.05.041 · Cited by 37
Targeted Therapy for Hepatocellular Carcinoma
Ohri, N., Kaubisch, A., Garg, M. K., & Guha, C. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.06.004 · Cited by 35
Daoudaki, M., & Fouzas, I. (2014) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-014-0296-7 · Cited by 34
Peptide vaccines for hepatocellular carcinoma
Nobuoka, D., Yoshikawa, T., Sawada, Y., Fujiwara, T., & Nakatsura, T. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22473 · Cited by 33
Dewhirst, M. W., Landon, C. D., Hofmann, C. L., & Stauffer, P. R. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.02.009 · Cited by 33
Pan, Z., Chen, C., Long, H., Lei, C., TANG, G., Li, L., Feng, J., & Chen, F. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1279 · Cited by 29
Iwama, T., Uchida, T., Sawada, Y., Tsuchiya, N., Sugai, S., Fujinami, N., Shimomura, M., Yoshikawa, T., Zhang, R., Uemura, Y., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.084 · Cited by 27
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma
Farra, R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i30.8994 · Cited by 25
Deng, X., Yin, Z., Zhou, Z., Wang, Y., Zhang, F., Hu, Q., Yang, Y., Lu, J., Wu, Y. F., Sheng, W., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03122 · Cited by 25
Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma
Kamel, R., Amr, K. S., Afify, M., Elhosary, Y. A., Hegazy, A. E., Fahim, H. H., & Ezzat, W. M. (2016) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2016.038 · Cited by 18
Yutani, S., Ueshima, K., Abe, K., Ishiguro, A., Eguchi, J., Matsueda, S., Komatsu, N., Shichijo, S., Yamada, A., Itoh, K., et al. (2015) · Journal of Immunology Research · doi:10.1155/2015/473909 · Cited by 17
de Souza, A. R., Reig, M., & Bruix, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225722 · Cited by 17
Wang, C., HANN, H.-W. L., Ye, Z., Hann, R. S., Wan, S., Ye, X., Block, P. D., Li, B., Myers, R. E., Wang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9429 · Cited by 15
Chen, C., Tsukamoto, H., & Machida, K. (2014) · Hepatology International · doi:10.1007/s12072-014-9545-5 · Cited by 10
Cited by
Liposomes: Advancements and innovation in the manufacturing process
Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.002 · Cited by 745
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
Lee, S. Y., Choi, J. W., Lee, J.-Y., Kim, D.-D., Kim, H.-C., & Cho, H.-J. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1480673 · Cited by 36
Metadata
- Authors
- Dutta, R., & Mahato, R. I.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 173
- Pages
- 106-117
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2583642351
- Cited by
- 280
- References
- 106
- FWCI
- 20.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.